Local News: Maryville, TN 

 | 

Sign Up

 | 

Sign In

Advertisment

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Alnylam Pharmaceuticals News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Alnylam Pharmaceuticals News

News on Alnylam Pharmaceuticals continually updated from thousands of sources around the net.

Yesterday | Customer Interaction Solutions

(ALNY) SqueezeTrigger Price is $17.097. There is $80,587,395.00 That...

BUYINS.NET / www.squeezetrigger.com is monitoring ALNYLAM PHARMACEU in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock.

Comment?

Related Topix: Biotech, Epidemic, Natural Disasters

Thu Dec 17, 2009

Freshnews

Regulus Therapeutics Receives Exclusive License for Intellectual...

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.

Comment?

Related Topix: Biotech, Isis Pharmaceuticals, Medicine, Healthcare Industry, California Institute of Technology, Inventions, Chemistry, Science

Wed Dec 09, 2009

Freshnews

Regulus Therapeutics Inc. presents: "MicroRNA: The Year in Review and a Look Ahead"

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

Comment?

Related Topix: Biotech, Isis Pharmaceuticals, Medicine, Healthcare Industry, Biology, Science

Tue Nov 24, 2009

PR-inside.com

Alnylam to Webcast Presentation at Piper Jaffray 21st Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Piper Jaffray 21 st Annual Health Care Conference on Wednesday, December 2, 2009, at 8:00 a.m. ET at The New York Palace Hotel.

Comment?

Related Topix: Biotech

Mon Nov 23, 2009

MediLexicon

Gene Silencing To Boost Biological Drug Yields

An American biotech company is planning to use a new technique called RNA interference to boost yields of biological drugs by improving the performance of drug-producing cell cultures.

Comment?

Related Topix: Biotech, Cambridge, MA, Health

Fri Nov 20, 2009

News@nature.com

Gene silencing predicted to improve drug manufacturing

Biotech firm hopes to use RNA interference to boost drug yields. Chinese hamster ovary cells: the workhorse of the biological drug market.

Comment?

Related Topix: Biotech, Cambridge, MA

Wed Nov 18, 2009

Drugs.com

Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi...

Nov 18, 2009 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

Comment?

Related Topix: Law, Biotech, Boston, MA Metro, Colorectal Health, Medicine, Health, Oncology

Fri Nov 13, 2009

BioSpace

Alnylam Pharmaceuticals Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day

Alnylam is developing RNAi therapeutics for the treatment of both RSV infection and ATTR, amongst other pipeline programs.

Comment?

Related Topix: Biotech

Thu Nov 12, 2009

Zacks Analyst Blog

Wider Loss for Alnylam

Alnylam Pharmaceuticals Inc. reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents.

Comment?

Related Topix: Biotech, Cambridge, MA

Mon Nov 09, 2009

Earth Times

Alnylam to Webcast R&D Day on Thursday, November 12, 2009

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the "Investors" section of the company's website at www.alnylam.com . Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel ...

Comment?

Related Topix: Biotech, Sport Movies, Drama Movies, Comedy Movies, College

Thu Nov 05, 2009

Drugs.com

Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at...

Nov 5, 2009 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that ...

Comment?

Related Topix: Biotech, World News, Japan

MarketWatch

Biotech Stocks: BioCryst, Isis rally; Alnylam falls

Drug stocks gained Thursday, but shares of Alnylam Pharmaceuticals fell a day after the company reported a widened third-quarter loss and said its search for research partners is taking longer than expected.

Comment?

Related Topix: Biotech, Isis Pharmaceuticals, Medicine, Healthcare Industry, Metal, Isis, Science / Technology, BioCryst Pharmaceuticals, Financial Markets

Business Wire

Public relations, press release distribution, investor relations, SEC filing

OMAHA, Neb.-- --Fred Tomczyk, president and chief executive officer of TD AMERITRADE Holding Corporation , will give a presentation and Q&A session on Thursday, Nov.

Comment?

Related Topix: Omaha, NE Metro, Financial Services, Ameritrade Holding, Investment Services, Biotech, Medicine, Healthcare Industry, Alkermes, Startups, Echelon, Computers, Software

Tue Nov 03, 2009

Customer Interaction Solutions

Here It Here First!! Sign Up For Our Free Newsletter!! (OTCBB: TNUS - ...

Here It Here First!! Sign Up For Our Free Newsletter!! "Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems to Test Proprietary Mushroom Compounds in Suppressing Alzeheimer's Disease" STOCK MARKETING INC PRESENTS : www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit ...

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Nutraceutical International, Marketing, Telecom, Electronics, Ixia, Amedisys, Salix Pharmaceuticals

Sun Nov 01, 2009

Customer Interaction Solutions

SmarTrend, our proprietary pattern recognition system, called a...

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Alnylam Pharmaceuticals on October 02, 2009 at $21.42. Since then, Alnylam Pharmaceuticals has returned 20.2% as of Friday's recent price of $17.10. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial.

Comment?

Related Topix: Biotech

Fri Oct 30, 2009

Freshnews

Alnylam to Webcast Conference Call Discussing Third Quarter 2009 Financial Results

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2009 on Wednesday, November 4, 2009, after the U.S. financial markets close.

Comment?

Related Topix: Biotech

Wed Oct 28, 2009

Medical News

United States Patent and Trademark Office allows a patent application within a Esaua patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

Comment?

Related Topix: Patent / Trademark Law, Law, Biotech, Isis Pharmaceuticals, Medicine, Healthcare Industry

Fri Oct 09, 2009

BioSpace

Alnylam Pharmaceuticals Chief Foresees Another Gene-Silencing Spin-Off

Xconomy.com -- Alnylam Pharmaceuticals had more than $470 million in the bank as of the last official count at the end of June, so it struck me as odd that the Cambridge, MA-based developer of gene-silencing drugs was a presenter along with dozens of cash-starved biotech startups at the MassBio Investors Forum in Boston yesterday.

Comment?

Related Topix: Biotech, Cambridge, MA

Wed Oct 07, 2009

The Boston Globe

Mass. biotech firms urged to remain independent

Ted Torphy, chief scientific officer at Johnson & Johnson, was the moderator at the MassBio Investors Forum at the Sheraton Boston.

Comment?

Related Topix: Biotech, Science / Technology, Johnson and Johnson, Medicine, Healthcare Industry, Boston, MA Metro, Boston Metro

Mon Oct 05, 2009

Bizjournals

Emily Walsh

Emily Walsh is on to a new adventure. After two years as a program manager at Alnylam Pharmaceuticals, she is striking out on her own to form a new biotechnology firm.

Comment?

Related Topix: Biotech

Maryville Jobs

Also on Topix